Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients

Journal of Immunology

Volumn 188, Issue 7, 2012, Pages 3532-3541

  Beurskens, Frank J ^a   Lindorfer, Margaret A ^b   Farooqui, Mohammed ^c   Beum, Paul V ^b   Engelberts, Patrick ^a   Mackus, Wendy J M ^a,d   Parren, Paul W H I ^a   Wiestner, Adrian ^c   Taylor, Ronald P ^b  

^a GENMAB   (Netherlands)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C3D; CYCLOPHOSPHAMIDE; FLUDARABINE; OFATUMUMAB; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MULTIPLE CYCLE TREATMENT; OPSONIZATION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTE SUBSETS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT C4B; COMPLEMENT SYSTEM PROTEINS; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; OPSONIN PROTEINS; VIDARABINE;

EID: 84859402731     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103693     Document Type: Article

References (51)

1. Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6: 343-357.
2. Parren, P. W. H. I., and J. G. J. van de Winkel. 2008. An integrated science-based approach to drug development. Curr. Opin. Immunol. 20: 426-430.
3. Bologna, L., E. Gotti, M. Manganini, A. Rambaldi, T. Intermesoli, M. Introna, and J. Golay. 2011. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J. Immunol. 186: 3762-3769.
4. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446. (Pubitemid 30208162)
5. Cartron, G., H. Watier, J. Golay, and P. Solal-Celigny. 2004. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104: 2635-2642. (Pubitemid 39434941)
6. Teeling, J. L., R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. Parren, C. E. Hack, M. Dechant, et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800. (Pubitemid 39202289)
7. Lefebvre, M.-L., S. W. Krause, M. Salcedo, and A. Nardin. 2006. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 29: 388-397. (Pubitemid 44288951)
8. Teeling, J. L., W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-371. (Pubitemid 43939148)
9. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837. (Pubitemid 47332625)
10. Beum, P. V., M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. Parren, J. G. van de Winkel, and R. P. Taylor. 2008. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181: 822-832.
11. Taylor, R. P., and M. A. Lindorfer. 2008. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20: 444-449.
12. Walport, M. J. 2001. Complement. First of two parts. N. Engl. J. Med. 344: 1058-1066.
13. Dunkelberger, J. R., and W. C. Song. 2010. Complement and its role in innate and adaptive immune responses. Cell Res. 20: 34-50.
14. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
15. Zent, C. S., C. R. Secreto, B. R. LaPlant, N. D. Bone, T. G. Call, T. D. Shanafelt, D. F. Jelinek, R. C. Tschumper, and N. E. Kay. 2008. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk. Res. 32: 1849-1856.
16. Zent, C. S., J. B. Chen, R. C. Kurten, G. P. Kaushal, H. M. Lacy, and S. A. Schichman. 2004. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk. Res. 28: 495-507. (Pubitemid 38453062)
17. Maloney, D. G., A. J. Grillo-López, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195. (Pubitemid 27392702)
18. Byrd, J. C., T. Murphy, R. S. Howard, M. S. Lucas, A. Goodrich, K. Park, M. Pearson, J. K. Waselenko, G. Ling, M. R. Grever, et al. 2001. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19: 2153-2164. (Pubitemid 32366969)
19. O'Brien, S. M., H. Kantarjian, D. A. Thomas, F. J. Giles, E. J. Freireich, J. Cortes, S. Lerner, and M. J. Keating. 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19: 2165-2170. (Pubitemid 32366970)
20. Bleeker, W. K., M. E. Munk, W. J. M. Mackus, J. H. N. van den Brakel, M. Pluyter, M. J. Glennie, J. G. J. van de Winkel, and P. W. H. I. Parren. 2008. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140: 303-312.
21. Pawluczkowycz, A.W., F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. J. van de Winkel, P. W. H. I. Parren, and R. P. Taylor. 2009. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183: 749-758.
22. Cheson, B. D. 2010. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28: 3525-3530.
23. Williams, M. E., J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor. 2006. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 177: 7435-7443. (Pubitemid 44715114)
24. Aue, G., M. A. Lindorfer, P. V. Beum, A. W. Pawluczkowycz, B. Vire, T. Hughes, R. P. Taylor, and A. Wiestner. 2010. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 95: 329-332.
25. Kennedy, A. D., M. D. Solga, T. A. Schuman, A. W. Chi, M. A. Lindorfer, W. M. Sutherland, P. L. Foley, and R. P. Taylor. 2003. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101: 1071-1079. (Pubitemid 36139381)
26. Beum, P. V., M. A. Lindorfer, B. E. Hall, T. C. George, K. Frost, P. J. Morrissey, and R. P. Taylor. 2006. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. J. Immunol. Methods 317: 90-99. (Pubitemid 44809210)
27. Beum, P. V., A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor. 2006. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176: 2600-2609. (Pubitemid 43201712)
28. Beum, P. V., D. A. Mack, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor. 2008. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J. Immunol. 181: 8120-8132.
29. Beum, P. V., M. A. Lindorfer, and R. P. Taylor. 2008. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J. Immunol. 181: 2916-2924.
30. Kennedy, A. D., P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor. 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 172: 3280-3288. (Pubitemid 38263720)
31. Lindorfer, M. A., A. W. Pawluczkowycz, E. M. Peek, K. Hickman, R. P. Taylor, and C. J. Parker. 2010. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115: 2283-2291.
32. Beekman, J. M., C. E. van der Poel, J. A. van der Linden, D. L. van den Berg, P. V. van den Berghe, J. G. van de Winkel, and J. H. Leusen. 2008. Filamin A stabilizes Fc g RI surface expression and prevents its lysosomal routing. J. Immunol. 180: 3938-3945.
33. Whaley, K., and J. North. 1997. Haemolytic assays for whole complement activity and individual components. In Complement. A Practical Approach. A. W. Dodds, and R. B. Sim, eds. IRL at Oxford University Press, Oxford, p. 19-48.
34. DiLillo, D. J., A. W. Pawluczkowycz, W. Peng, A. D. Kennedy, P. V. Beum, M. A. Lindorfer, and R. P. Taylor. 2006. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol. Immunol. 43: 1010-1019. (Pubitemid 41814418)
35. Schreiber, A. D., and M. M. Frank. 1972. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 51: 575-582.
36. Gong, Q., Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174: 817-826. (Pubitemid 40094277)
37. Rawstron, A. C., F. L. Bennett, S. J. M. O'Connor, M. Kwok, J. A. L. Fenton, M. Plummer, R. de Tute, R. G. Owen, S. J. Richards, A. S. Jack, and P. Hillmen. 2008. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N. Engl. J. Med. 359: 575-583.
38. Shanafelt, T. D., N. E. Kay, G. Jenkins, T. G. Call, C. S. Zent, D. F. Jelinek, W. G. Morice, J. Boysen, L. Zakko, S. Schwager, et al. 2009. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 113: 4188-4196.
39. Cooper, I. A., J. C. Ding, P. B. Adams, M. A. Quinn, andM. Brettell. 1979. Intensive leukapheresis in the management of cytopenias in patients with chronic lymphocytic leukaemia (CLL) and lymphocytic lymphoma. Am. J. Hematol. 6: 387-398. (Pubitemid 10189269)
40. Beers, S. A., R. R. French, H. T. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. J. Kim, K. L. Cox, et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201.
41. Lim, S. H., A. T. Vaughan, M. Ashton-Key, E. L. Williams, S. V. Dixon, H. T. Chan, S. A. Beers, R. R. French, K. L. Cox, A. J. Davies, et al. 2011. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118: 2530-2540.
42. Beum, P. V., E. M. Peek, M. A. Lindorfer, F. J. Beurskens, P. J. Engelberts, P. W. Parren, J. G. J. van de Winkel, and R. P. Taylor. 2011. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J. Immunol. 187: 3438-3447.
43. Ziccardi, R. J. 1982. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J. Immunol. 128: 2505-2508. (Pubitemid 12124470)
44. Klepfish, A., A. Schattner, H. Ghoti, and E. A. Rachmilewitz. 2007. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol. 8: 361-362. (Pubitemid 46464534)
45. Taylor, R. 2007. Fresh frozen plasma as a complement source. Lancet Oncol. 8: 370-371. (Pubitemid 46621766)
46. Xu, W., K. R. Miao, D. X. Zhu, C. Fang, H. Y. Zhu, H. J. Dong, D. M. Wang, Y. J. Wu, C. Qiao, and J. Y. Li. 2011. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int. J. Cancer 128: 2192-2201.
47. Bowles, J. A., and G. J. Weiner. 2005. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J. Immunol. Methods 304: 88-99. (Pubitemid 41262223)
48. Bowles, J. A., S.-Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M. A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al. 2006. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108: 2648-2654.
49. Berdeja, J. G., A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn. 2007. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin. Cancer Res. 13: 2392-2399. (Pubitemid 46698589)
50. Bhat, R., and C. Watzl. 2007. Serial killing of tumor cells by human natural killer cells - enhancement by therapeutic antibodies. PLoS ONE 2: e326.
51. Veeramani, S., S. Y. Wang, C. Dahle, S. Blackwell, L. Jacobus, T. Knutson, A. Button, B. K. Link, and G. J. Weiner. 2011. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118: 3347-3349.